The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
The Russian pharmaceutical company Binnopharm Group is aiming to become one of the leading players in the domestic market in years to come and to begin exports of its drugs to foreign markets. 22 August 2024
Texas, USA-based Coya Therapeutics announced that Arun Swaminathan has been promoted to the role of chief executive (CEO) effective November 1, 2024. 22 August 2024
BioMarin Pharmaceutical (Nasdaq: BMRN) has announced key leadership changes, appointing Greg Friberg as chief research and development officer, and James Sabry as chief business officer. 21 August 2024
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the biologics license application (BLA) for linvoseltamab.. 21 August 2024
Shares of US clinical-stage biotech Kymera Therapeutics, Inc. declined 5% to $42.05 after it announced a public offering of $200 million in common stock and pre-funded warrants. 21 August 2024
Swipha, a leading Nigerian pharmaceutical manufacturer, has received prequalification from the World Health Organization (WHO) for its sulfadoxine-pyrimethamine (SP) drug. 21 August 2024
Indian drug maker Dr Reddy’s Laboratories and its subsidiary Aurigene Pharmaceutical Services have signed a non-binding, memorandum of understanding (MoU) with US start-up Kainomyx, for the development and commercialization of affordable anti-malarial drug in the USA, Europe, and in low and middle-income countries. 21 August 2024
The US Food and Drug Administration (FDA) has granted tentative approval of Liquidia Corp’s Yutrepia (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). 21 August 2024
A recent survey conducted by Magnolia Market Access provides insight directly from insurers, revealing in no uncertain terms that insurers plan to restrict coverage in Medicare Part D because of the USA’s Inflation Reduction Act (IRA). 21 August 2024
FUJIFILM Diosynth Biotechnologies has hosted a celebration for the opening of its microbial fermentation manufacturing facility in Billingham, UK. 21 August 2024
Swiss mitochondrial therapeutics developer Vandria today announced the second closing of its Series A financing, bringing the final amount raised to date to $30.7 million (28.3 million francs). 21 August 2024
Pathalys Pharma, a private biopharmaceutical company based in North Carolina, USA, has announced the successful closure of a $105 million series B financing round. 21 August 2024
Germany's pharmaceutical sector is on high alert for potential drug shortages, following China’s recent intensification of its espionage laws. 21 August 2024
GSK (LSE: GSK) has received Breakthrough Therapy designation from the US Food and Drug Administration for GSK'227, an investigational B7-H3-targeted antibody-drug conjugate (ADC). 20 August 2024
AstraZeneca (LSE: AZN) has announced that Fasenra (benralizumab) has picked up a new approval from China's National Medical Products Administration (NMPA). 20 August 2024
Danish biotech Adcendo has signed a licensing agreement with Multitude Therapeutics for the global development and commercialization of ADCE-T02. 20 August 2024
The US Food and Drug Administration (FDA) has approved Lazcluze (lazertinib) in combination with Rybrevant (amivantamab-vmjw), from Janssen Biotech, for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). 20 August 2024